Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes. Immuneering's technologies have proven exceptionally rapid and capital-efficient in creating its pipeline. Concurrent with its internal programs, the company provides unparalleled computational biology services to leading pharmaceutical and biotechnology companies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/17/19 | $17,000,000 | Series A |
Boxcar | undisclosed |
| 01/23/20 | $3,000,000 | Series A |
Boxcar | undisclosed |
